diagnost tool
look conserv buy pt
deliv in-lin organ revenu growth beat bottom line
continu demonstr global leadership posit anim health diagnost
customari guid guidanc earlier believ set
bar readili achiev exceed despit fact came street
expect remain best-in-class larg cap growth leader highli attract
global anim health market reiter buy rate trim pt
use multipl adj ep estim
rev organ match our/street gm
y/i beat om y/i beat
adj ep y/i beat
growth segment deliv beat consum larg off-set
miss refer lab vs estim attribut extrem weather
eu coupl focu econom valu index initi solid growth came
consum servic beat softwar imag system
beat rapid assay beat off-set miss
refer lab vs instrument vs
slight hiccup refer lab look like anomali us deliv refer
lab growth report organ forecast
manag attribut unseason hot weather europ moder ou
refer lab growth concern given materi
competitor refer lab segment europ thu think larg
anomali growth rate refer lab averag prior four quarter
think well posit rebound go forward
guid initi revenue guid rep
cc y/i prior prior
expect adj ep rep cc y/i vs prior
delta ep guid street due
view reduct tax benefit relat share
base stock comp expect organ revenue growth dx
recur growth in-lin trend adjust benefit new
revenu account standard histor deliv fy result well excess
initi fy guid provid call trend expect continu
guid lower high end organ growth guid bp
expect rev
rais adj ep guid midpoint
expect ep rep
model trim rev
rev take conserv view
reiter adj ep y/i trim revenue growth
trim adj ep y/i
price close busi novemb
global leader anim health diagnost
instrument lab test softwar sell direct
global sale rep
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
complet sale forc expans complet direct sale
forc expans direct rep remain track complet
ou expans earli upon complet employ ou
rep vs previous expect slight disrupt near-term rep
territori tweak expect smooth transit time deep
experi scale commerci engin rep all-in look
maintain leadership rep complet
acquisit abaxi earlier year view abaxi may see near-term
disrupt integr abaxi busi global
play long term august analyst day initi
year anim dx revenue spend target compound-annual-growth-rate led
growth ou us think could grow revenu faster
estim exclud softwar year see upsid
guid driven lack meaning competitor ou refer
lab busi earli phase newer product launch integr challeng
zoetis/abaxi may allow execut even better near-term traction
new us ou sale rep share repurchas could exceed
state goal share count recal think intern anim health
diagnost market grow current size
buy unchang target price novemb
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price novemb
diagnost tool
buy unchang target price novemb
diagnost tool
